mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2011-657mrj-342Research ArticleСтатьиArticlesЭффективность и безопасностьнестероидных противовоспалительных препаратов:что мы узнали в 2010 году?Effektivnost' i bezopasnost'nesteroidnykh protivovospalitel'nykh preparatov:chto my uznali v 2010 godu?KarateyevAndrei EvgenyevichKarateyevAndrei Evgenyevichaekarateev@rambler.ru20111503201151№1 (2011)7983Copyright © Karateyev A.E., 20112011Karateyev A.E.Karateyev A.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/342References<div><p>Martina S., Vesta K., Ripley T. Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother 2005;39(5):854-62.</p><p>Brooks P., Kubler P. Etoricoxib for arthritis and pain management. Ther Clin Risk Manag 2006;2(1):45-57.</p><p>Ramey D., Watson D., Yu C. et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin 2005;21(5):715-22.</p><p>Hunt R., Harper S., Watson D. et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003;98(8):1725-33.</p><p>Curtis S., Ko A., Bolognese J. et al. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib. Сurr Med Res Opin 2006;22(12):2365-74.</p><p>Cannon C., Curtis S., FitzGerald G. et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006;18;368(9549):1771-81.</p><p>Ziegler S., Huscher D., Karberg K. et al. Trends in treatment and outcomes of rheumatoid arthritis in Germany 1997-2007: results from the National Database of the German Collaborative arthritis Centers. ARD 2010;69:1803-8.</p><p>Peloso P., Mehta A., Wang H. et al. Etoricoxib improves pain in rheumatoid arthritis (RA) patients on background corticosteroid and biologic therapies. EULAR-2010, AB0375.</p><p>Moore R., Smugar S., Wang H. et al. Numbers-needed-to-treat analyses-do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials. Pain 2010;151(3):592-7.</p><p>Brattwall M., Turan I., Jakobsson J. Pain management after elective hallux valgus surgery: a prospective randomized double-blind study comparing etoricoxib and tramadol. Anesth Analg 2010;111(2):544-9.</p><p>Jansen J., Gaugris S., Choy E. et al. Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis. Pharmacoeconomics 2010;28(4):323-44.</p><p>Lin H., Cheng T., Wang J. et al. Etoricoxib improves pain, function and quality of life: results of a real-world effectiveness trial. Int J Rheum Dis 2010;13(2):144-50.</p><p>Lanas A., Tornero J., Zamorano J. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study. Ann Rheum Dis 2010;69(8):1453-8.</p><p>Chan F., Lanas A., Scheiman J. et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010;376:173-9.</p><p>Peric A., Toskic-Radojicic M., Dobric S. et al. Are COX-2 inhibitors preferable to combined NSAID and PPI in countries with moderate health service expenditures? J Eval Clin Pract 2010;16(6):1090-5.</p><p>Fosbol E., Folke F., Jacobsen S. et al. CauseSpecific Cardiovascular Risk Associated With Nonsteroidal Antiinflammatory Drugs Among Healthy Individuals. Circ Cardiovasc Qual Outcomes 2010;3:395-405.</p><p>Gudbjornsson B., Thorsteinsson S., Sigvaldason H. et al. Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults - a nationwide registry-based study. Eur J Clin Pharmacol 2010;66:619-25.</p><p>Singh G., Mannalithara A., Sehgal A. et al. The Risk of Complicated Gastroduodenal Ulcers with Naproxen Is Dose-Dependent. Arthr Rheum 2010;62(10):926.</p></div><br /><div><p>Martina S., Vesta K., Ripley T. Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother 2005;39(5):854-62.</p><p>Brooks P., Kubler P. Etoricoxib for arthritis and pain management. Ther Clin Risk Manag 2006;2(1):45-57.</p><p>Ramey D., Watson D., Yu C. et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin 2005;21(5):715-22.</p><p>Hunt R., Harper S., Watson D. et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003;98(8):1725-33.</p><p>Curtis S., Ko A., Bolognese J. et al. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib. Сurr Med Res Opin 2006;22(12):2365-74.</p><p>Cannon C., Curtis S., FitzGerald G. et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006;18;368(9549):1771-81.</p><p>Ziegler S., Huscher D., Karberg K. et al. Trends in treatment and outcomes of rheumatoid arthritis in Germany 1997-2007: results from the National Database of the German Collaborative arthritis Centers. ARD 2010;69:1803-8.</p><p>Peloso P., Mehta A., Wang H. et al. Etoricoxib improves pain in rheumatoid arthritis (RA) patients on background corticosteroid and biologic therapies. EULAR-2010, AB0375.</p><p>Moore R., Smugar S., Wang H. et al. Numbers-needed-to-treat analyses-do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials. Pain 2010;151(3):592-7.</p><p>Brattwall M., Turan I., Jakobsson J. Pain management after elective hallux valgus surgery: a prospective randomized double-blind study comparing etoricoxib and tramadol. Anesth Analg 2010;111(2):544-9.</p><p>Jansen J., Gaugris S., Choy E. et al. Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis. Pharmacoeconomics 2010;28(4):323-44.</p><p>Lin H., Cheng T., Wang J. et al. Etoricoxib improves pain, function and quality of life: results of a real-world effectiveness trial. Int J Rheum Dis 2010;13(2):144-50.</p><p>Lanas A., Tornero J., Zamorano J. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study. Ann Rheum Dis 2010;69(8):1453-8.</p><p>Chan F., Lanas A., Scheiman J. et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010;376:173-9.</p><p>Peric A., Toskic-Radojicic M., Dobric S. et al. Are COX-2 inhibitors preferable to combined NSAID and PPI in countries with moderate health service expenditures? J Eval Clin Pract 2010;16(6):1090-5.</p><p>Fosbol E., Folke F., Jacobsen S. et al. CauseSpecific Cardiovascular Risk Associated With Nonsteroidal Antiinflammatory Drugs Among Healthy Individuals. Circ Cardiovasc Qual Outcomes 2010;3:395-405.</p><p>Gudbjornsson B., Thorsteinsson S., Sigvaldason H. et al. Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults - a nationwide registry-based study. Eur J Clin Pharmacol 2010;66:619-25.</p><p>Singh G., Mannalithara A., Sehgal A. et al. The Risk of Complicated Gastroduodenal Ulcers with Naproxen Is Dose-Dependent. Arthr Rheum 2010;62(10):926.</p></div><br />
The authors declare that there are no conflicts of interest present.